Challenges of antiangiogenic cancer therapy: Trials and errors, and renewed hope

Journal of Cellular and Molecular Medicine

Volumn 11, Issue 3, 2007, Pages 374-382

  Medina, Miguel Ángel ^a   Muñoz Ch́puli, Ramón ^a   Quesada, Ana R ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Angiogenesis; Antiangiogenic therapy; Bevacizumab

Indexed keywords

ANGIOGENESIS INHIBITOR; TUMOR MARKER;

ANIMAL; ARTICLE; HUMAN; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY);

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL;

EID: 34547346812     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2007.00056.x     Document Type: Article

References (57)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 9 : 653 60.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005 438 : 932 6.
3. Muñoz-Chápuli R, Quesada AR, Medina MA. Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci. 2004 61 : 2224 43.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 100 : 57 70.
5. Folkman J, Hahnfeldt P, Hlatky L. Cancer: Looking outside the genome. Nat Rev Mol Cell Biol. 2000 1 : 76 9.
6. Kerbel RS. Tumor angiogenesis: Past, present and the near future. Carcinogenesis. 2000 21 : 505 15.
7. Matter A. Tumor angiogenesis as a therapeutic target. Drug Disc Today. 2001 6 : 1005 24.
8. Quesada AR, Muñoz-Chápuli R, Medina MA. Anti-angiogenic drugs: From bench to clinical trials. Med Res Rev. 2006 26 : 483 530.
9. Norrby N. In vivo models of angiogenesis. J Cell Mol Med. 2006 10 : 588 612.
10. Augustin HG. Antiangiogenic tumour therapy: Will it work? Trends Pharmacol Sci. 1998 19 : 216 22.
11. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003 3 : 401 10.
12. Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. Br J Cancer. 2003 89 : 8 14.
13. Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer. 2006 6 : 626 35.
14. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002 98 : 883 93.
15. Solorzano CC, Jung YD, Bucana CD, McConkey DJ, Gallick GE, McMahon G, Ellis LM. In vivo intracellular signaling as a marker of antiangiogenic activity. Cancer Res. 2001 61 : 7048 51.
16. Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell'Agnolo C, Gobbi A, Martinelli G, Bertolini F. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 2001 61 : 4341 4.
17. Baish JW, Jain RK. Fractals and cancer. Cancer Res. 2000 60 : 3683 8.
18. Dowlati A, Haaga J, Remick SC, Spiro TP, Gerson SL, Liu L, Berger SJ, Berger NA, Willson JK. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res. 2001 7 : 2971 6.
19. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003 9 : 685 93.
20. McDonald DM, Choyke PL. Imaging of angiogenesis: From microscope to clinic. Nat Med. 2003 9 : 713 25.
21. Sweeney CJ, Miller KD, Sledge Jr GW. Resistance in the anti-angiogenic era: Nay-saying or a word of caution? Trends Mol Med. 2003 9 : 24 9.
22. Kaur M, Reed E, Sartor O, Dahut W, Figg WD. Suramin's development: What did we learn? Invest New Drugs. 2002 20 : 209 19.
23. Vogelzang NJ, Karrison T, Stadler WM, García J, Cohn H, Troeger T, Giannone L, Arrieta R, Ratain MJ, Vokes EE. A phase II trial of suramine monthly ×3 for hormone-refractory prostate carcinoma. Cancer. 2004 100 : 65 71.
24. Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol. 2007 170 : 1 15.
25. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. Nat Rev Cancer. 2006 6 : 835 45.
26. Ganss R. Tumor stroma fosters neovascularization by recruitment of progenitr cells into the tumor bed. J Cell Mol Med. 2006 10 : 857 65.
27. Anghelina M, Krishnan P, Moldovan L, Moldovan NI. Monocytes/macrophages cooperate with progenitor cells during neovascularization and tissue repair: Conversion of cell columns into fibrovascular bundles. Am J Pathol. 2006 168 : 529 41.
28. Anghelina M, Moldovan L, Zabuawala T, Ostrowski MC, Moldovan NI. A subpopulation of peritoneal macrophages form capillarylike lumens and branching patterns in vitro. J Cell Mol Med. 2006 10 : 708 15.
29. Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G, Menard S, Gatter KC, Harris AL, Fox S, Buyse M, Pilotti S. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol. 1997 151 : 1417 23.
30. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999 284 : 1994 8.
31. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer. 2003 3 : 411 21.
32. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol. 2000 156 : 361 81.
33. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature. 2005 438 : 946 53.
34. Jain RK. The next frontier of molecular medicine: Delivery of therapeutics. Nat Med. 1998 4 : 655 7.
35. Madhusudan S, Harris AL. Drug inhibition of angio-genesis. Curr Opinion Pharmacol. 2002 2 : 403 14.
36. Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin S, Griffing S, Novotny W, Holmgren E, Kabbinavar F. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as a first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol Meeting. 2003 3646.
37. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin S, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 350 : 2335 42.
38. Mayer RJ. Two steps forward in the treatment of col-orectal cancer. N Engl J Med. 2004 350 : 2406 8.
39. Giantonio BJ. Bevacizumab for the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings. Semin Oncol. 2006 33 : S15 8.
40. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 355 : 2542 50.
41. Reddy GK, Bukowski RM. Sorafenib: Recent update on activity as a single agent in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma. Clin Genitourin Cancer. 2006 4 : 246 8.
42. Demetri GD, van Oosterrom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heirinch MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet. 2006 368 : 1329 38.
43. Eto M, Naito S. Molecular targeting therapy for renal cell carcinoma. Int J Clin Oncol. 2006 11 : 209 13.
44. Sparano JA, Gray R, Giantonio B, O'Dwyer P, Comis RL. Evaluating antiangiogenesis agents in the clinic: The Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Clin Cancer Res. 2004 10 : 1206 11.
45. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med. 2001 7 : 987 9.
46. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D'Amato RJ, Kerbel RS. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell. 2005 7 : 101 11.
47. Gasparini G. Metronomic scheduling: The future of chemotherapy? Lancet Oncol. 2001 2 : 733 40.
48. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004 4 : 423 36.
49. García-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R. Tumor response to radiotherapy regulated by endothe-lial cell apoptosis. Science. 2003 300 : 964 7.
50. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 1990 9 : 267 82.
51. Thorpe PE, Chaplin DJ, Blakey DC. The First International Conference on Vascular Targeting: Meeting overview. Cancer Res. 2003 63 : 1144 7.
52. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell. 2004 5 : 13 7.
53. Shannon AM., Bouchier-Hayes DJ, Condron CH, Toomey D. Tumor hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev. 2003 29 : 297 307.
54. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res. 2003 37 : 179 92.
55. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 352 : 1071 80.
56. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma prevention trial. N Engl J Med. 2005 352 : 1092 102.
57. Albini A, Tosetti F, Benelli R, Noonan DM. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res. 2005 65 : 10637 41.